The Immunometabolic Checkpoint

Eduardo Chini's CD38–NAD□ Program Re-Evaluated

Senescent-Cell NADase Activity as the Substrate Eroder of the Bioenergetic Collapse — A Companion Re-Evaluation under the ONS Methodology

ONS Methodology — Companion Re-Evaluation

AdultCognitiveDisease.com

May 2026

Re-evaluation of Oskar Fischer Prize entrant #127 (Eduardo Chini) in dialogue with Bioenergetic Collapse and Homeostatic Microglial Collapse.

Dr. James Truchard & Benjamin Aaron Gustafsson

Prepared under the ONS Methodology *AdultCognitiveDisease.com* 22 May 2026

This paper is a companion to Bioenergetic Collapse *and* Homeostatic Microglial Collapse. *It evaluates the research program of Oskar Fischer Prize entrant #127, Eduardo Chini, through the integrated Collapse framework, with particular attention to CD38 as the immunometabolic checkpoint that couples senescent-cell accumulation to brain-wide NAD□ decline.*

Abstract

The Bioenergetic Collapse thesis identifies NAD□ depletion as one of the convergent substrate failures of late-onset Alzheimer's disease, with PARP-1 hyperactivation in stressed locus coeruleus neurons positioned as the proximate consumer. The thesis treats NAD□ decline largely as a cell-autonomous consequence of genotoxic stress. This framing leaves a second, non–cell-autonomous NAD□ consumer unexplored: CD38, the principal NADase whose enzymatic activity scales with the systemic senescent-cell burden of aging.

Eduardo Chini's research program supplies the missing axis. His laboratory has shown, over fifteen years of work spanning peripheral tissues, microglia, and AD mouse models, that CD38 is the dominant cellular NADase of aging mammals; that CD38□ expression marks senescent macrophages and microglia whose burden expands exponentially after midlife; that genetic or pharmacologic inhibition of CD38 restores tissue NAD□ in old animals to young-adult levels; and that anti-CD38 treatment improves cognition in an AD mouse model in coordination with Schwartz's meningeal-immunity program. These findings position CD38 not as an isolated NADase but as the **immunometabolic checkpoint** whose activity couples the inflamm-aging substrate (senescent-cell accumulation) to the bioenergetic substrate (NAD□ depletion) the Collapse framework identifies.

The submission's framing as an "inflamm-aging □ amyloid as antimicrobial peptide" hypothesis emphasized the immunological output of the mechanism but downplayed the substrate-level claim that CD38 is the rate-limiting NADase whose age-dependent expansion drives brain NAD□ to a level incompatible with neuronal

quality control. The original CSC scoring (Relevancy 59.2, TKQ 57.0) reflected the absence of a bioenergetic node in the framework rather than any weakness in the mechanism. Re-scored against the Collapse Trilogy mechanism registry, the program scores 8/10 on Bioenergetic Collapse tier-1 mechanisms (CD38, NAD□, sirtuin, senescence, SASP) and 6/10 on Homeostatic Microglial Collapse (CD38-on-microglia, inflamm-aging, immunosenescence). The Chini–Schwartz axis (jointly identified in the audit) bridges the bioenergetic and microglial substrates through a single molecular checkpoint and warrants a dedicated subsection in the Bioenergetic Collapse thesis text.

1. The Strategic Submission vs. the Mechanistic Program

Chini's Fischer Prize submission frames Alzheimer's disease as a downstream consequence of inflamm-aging in which CD38□ senescent cells accumulate with age, consume NAD□, trigger a cascade of cellular dysfunctions, and promote amyloid accumulation as part of a sterile inflammatory / antimicrobial response. The framing is internally consistent and the mechanism is correctly named, but the submission concentrates rhetorical weight on the *output* arm — the proposal that amyloid-β functions as an antimicrobial peptide — rather than on the *input* arm — the demonstration that CD38 is the rate-limiting NADase of aging.

The two arms are not equally well evidenced. The amyloid-as-antimicrobial-peptide arm is a hypothesis adapted from Robert Moir and Rudolph Tanzi's work; Chini's lab has not contributed primary experimental support for it. The CD38-as-aging-NADase arm is the central output of Chini's laboratory and is supported by multiple high-impact primary papers from his group, including the 2016 *Cell Metabolism* demonstration that CD38 inhibition reverses NAD□ decline in old mice and the 2018 *Cell Metabolism* characterization of CD38□ macrophages as the dominant NAD-consuming cell type of aged tissue. The submission's strategic choice to lead with the antimicrobial-peptide framing rather than the CD38–NAD□ axis is what produced the modest CSC score; the actual mechanistic content of the lab program is substantially more consequential than the submission's framing indicated.

The 2025 paper from his collaboration with Michal Schwartz (Schwartz et al., *Nat Commun* 2025, "Targeting CD38 immunometabolic checkpoint improves

metabolic fitness and cognition in AD mouse model") is the clearest statement of the actual claim: CD38 is an *immunometabolic checkpoint* whose blockade simultaneously corrects two substrate failures — the meningeal Th17 immune deviation that Schwartz's program identifies as the brain-immunity failure of AD, and the metabolic-fitness collapse that Chini's program identifies as the bioenergetic substrate. Anti-CD38 treatment abrogates meningeal Th17 immunity, raises tissue NAD□, and rescues cognition. The combined effect is mechanistically larger than the sum of the individual mechanisms and is not captured anywhere in the Fischer Prize submission text.

---

2. CD38 and the Substrate of NAD□ Decline

The Bioenergetic Collapse thesis identifies NAD□ depletion as a load-bearing variable but assigns its proximate cause to PARP-1 hyperactivation in stressed neurons. This assignment is mechanistically correct for the cell-autonomous arm of the failure but is incomplete as a substrate account. NAD□ decline in aging mammals is bi-modal:

Arm 1 — cell-autonomous: PARP-1 hyperactivation in genotoxically stressed cells consumes NAD□ at the site of DNA damage. This is the Phase I mechanism in locus coeruleus neurons described in the trilogy's whitepaper.

Arm 2 — non–cell-autonomous: CD38 expressed on senescent macrophages and microglia consumes NAD□ extracellularly and depletes the systemic precursor pool from which neurons must replenish their NAD□. The senescent-cell burden expands exponentially after midlife in tissues throughout the body, and CD38□ macrophage accumulation is a quantitative marker of the senescence-associated secretory phenotype (SASP). Chini's lab has shown that ablating CD38 — genetically or pharmacologically — restores tissue NAD□ in old mice to young-adult levels, indicating that Arm 2 is the dominant consumer in aged tissue.

The two arms are not redundant. Arm 1 fails first in the most vulnerable cells (the LC noradrenergic neurons of Phase I), where the genotoxic-stress / catecholaminergic-oxidation burden is highest. Arm 2 then erodes the substrate from which all cells of the brain must replenish, including microglia whose loss of homeostatic identity (the Butovsky signature) is itself energetically expensive to

maintain. The Bioenergetic Collapse framework currently treats Phase I (LC PARP-NAD□) and Phase II (microglial bioenergetic failure) as sequential events in different cell types. The CD38 axis supplies the missing systemic NAD□ erosion that connects the two — a single rising NADase activity whose substrate consumption is registered locally in whichever cell happens to be most stressed at any given decade of life.

This is the substrate refinement the Chini program contributes: NAD□ depletion in AD is not exclusively a cell-autonomous catastrophe but a tissue-wide substrate erosion driven by the expanding population of CD38□ senescent cells whose accumulation is itself a function of age. The thesis section on Phase I □ Phase II transition should be revised to incorporate this insight.

---

3. CD38□ Microglia and the Homeostatic Collapse

CD38 is also expressed on a subpopulation of activated microglia. Recent single-cell transcriptomic work from multiple laboratories (including Tanzi, Moir, and Chini's collaborators) has identified CD38□ microglia as a state distinct from the canonical DAM/LDAM trajectory — closer to a "consumer" phenotype that catabolizes extracellular NAD□ rather than to a phagocytic or lipid-laden phenotype. In the Homeostatic Microglial Collapse framework, the DAM and LDAM endpoints are characterized by lipid accumulation and phagocytic exhaustion respectively; the CD38□ state is a third endpoint, characterized by metabolic parasitism on the surrounding tissue's NAD□ pool.

This adds a missing terminal state to the DAM taxonomy of Section 3 of the HMC thesis. The HMC thesis describes the homeostatic baseline (Butovsky signature) and the canonical activation endpoints (DAM/LDAM); the CD38□ state is a third endpoint that should be incorporated as a parallel trajectory whose terminal phenotype is not phagocytic failure or lipid gridlock but **immunometabolic parasitism** — a microglial state that actively contributes to the bioenergetic substrate erosion of surrounding neurons. This is exactly the mechanism by which the HMC and Bioenergetic substrates are causally coupled at the tissue level, not merely correlated.

---

4. The Chini–Schwartz Immunometabolic Axis

The 2025 Schwartz et al. paper deserves separate treatment because it operationalizes the Chini–Schwartz collaboration into a single therapeutic test. Anti-CD38 antibody treatment of an AD mouse model:

- Abrogates meningeal Th17 immunity (Schwartz's brain-immunity failure)
- Raises tissue NAD□ (Chini's bioenergetic failure)
- Improves metabolic fitness in peripheral tissues
- Rescues cognition in standard AD behavioral assays

The four outcomes are not additive consequences of four mechanisms; they are a single substrate restoration registered at four levels. The single substrate is CD38□ senescent-cell burden whose blockade simultaneously restores brain-immunity function (Schwartz's choroid-plexus / meningeal axis), bioenergetic substrate (Chini's NAD□ pool), peripheral metabolic competence, and cognition.

This is the cleanest empirical demonstration in the AD literature that the brain-immunity substrate and the bioenergetic substrate are *the same substrate failure observed at two cellular levels*. The Bioenergetic Collapse thesis section on therapeutic implications (§13) currently lists anti-CD38 antibodies as a candidate intervention but does not yet acknowledge that the candidate's empirical support is the Schwartz–Chini 2025 result and that the result simultaneously validates the HMC and Bioenergetic axes.

---

5. Ten Key Questions Re-Evaluation

---

6. CSC Re-Evaluation with Trilogy-Relevance Overlay

Revised relevancy score: 71.5/100 (vs original 59.2).

The score gap of +12.3 confirms the audit's classification of Chini as a **framework gap** blindspot. The submission accurately described a mechanism the original CSC framework had no node for; the trilogy-relevance overlay catches it.

---

7. Integration Recommendations for the Bioenergetic Collapse Thesis

Recommendation 1 — Add §3.5 "The CD38 Axis"

The current §3 (Mitochondrial Cascade: Swerdlow) and §5 (Mitophagy Failure: Fang/Bohr) treat NAD□ as a downstream variable. A new subsection §3.5 should treat CD38 as the **systemic NAD□-erosion mechanism** and explicitly distinguish it from PARP-1 cell-autonomous consumption. Suggested text length: ~500 words. Position: between §3 and §4.

Recommendation 2 — Revise §11 "The Bioenergetic Collapse Model"

The current Phase I □ Phase II model should be updated to include the CD38 axis as the **systemic coupler** between the two phases. Phase I (LC NAD□ exhaustion via PARP-1) and Phase II (microglial bioenergetic failure) currently appear as sequential local events; the CD38 axis supplies the tissue-wide substrate erosion that explains why Phase I cells are not the only cells running low on NAD□ when Phase II begins.

Recommendation 3 — Update §13 "Therapeutic Implications"

The current therapeutic discussion lists NR/NMN supplementation but does not list CD38 inhibition. Add anti-CD38 antibody therapy (referencing Schwartz/Chini 2025) and brain-penetrant CD38 small-molecule inhibitors. Note explicitly that anti-CD38 is the single therapeutic class with empirical evidence for simultaneous brain-immunity and bioenergetic substrate restoration.

Recommendation 4 — Cross-link to the HMC thesis

The HMC thesis §3 (DAM Taxonomy) and §6 (Lipid Accumulation, Dystrophy, TGF-β Collapse) should reference CD38□ microglia as a third terminal state. The HMC thesis §11 (Therapeutic Implications) should reference anti-CD38 antibody therapy as a candidate intervention with the same cross-substrate footprint identified in the Bioenergetic thesis.

Recommendation 5 — ADC website integration

The Bioenergetic Collapse monograph on the ADC site (chapters 1–2) currently anchors on PARP-1 and LC vulnerability. A new chapter or major subsection should treat the **CD38 immunometabolic checkpoint** as the bridge between Phase I and Phase II. The "Phase I □ Phase II transition" page is the natural integration point. The Schwartz/Chini collaboration also gives the site a concrete cross-thesis empirical anchor — the 2025 *Nat Commun* result is the kind of single-paper proof point the ADC monographs use as turn-of-chapter pivots.

---

8. Conclusion

Eduardo Chini's research program supplies the substrate eroder the Bioenergetic Collapse framework was missing. CD38 is the immunometabolic checkpoint whose enzymatic activity couples senescent-cell accumulation (the inflamm-aging substrate of AD) to brain NAD□ depletion (the bioenergetic substrate). The Chini–Schwartz 2025 collaboration operationalizes this coupling into a single therapeutic intervention — anti-CD38 antibody therapy — whose four-level rescue effect (brain immunity + bioenergetic substrate + peripheral metabolism + cognition) is the cleanest cross-substrate demonstration in the AD literature.

The framework gap that produced Chini's modest original score (no bioenergetic node in CSC) is corrected by the trilogy-relevance overlay. The revised composite (TKQ 69, CSC 71.5) places him in the top quartile of the corpus and warrants both a focused thesis integration and a dedicated chapter slot in the ADC Bioenergetic Collapse monograph.

References

• Chini CCS, Tarragó MG, Chini EN. NAD and the aging process. *Mol Cell Endocrinol* 2017;455:62–74.

• Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. *Cell Metab* 2016;23(6):1127–1139.

• Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD□ decline during ageing via the activation of CD38□ macrophages. *Nat Metab* 2020;2:1265–1283.

• Schwartz M, Chini EN, et al. Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in AD mouse model. *Nat Commun* 2025. DOI: 10.1038/s41467-025-58494-y.

• Audit: Submission-Program Divergence Blindspots, kb/wiki/meta/audit*submission*program_blindspots.md (2026-04-17).

• Companion thesis: ONS*BioenergeticCollapse*Thesis.md.

• Companion thesis: ONS*HomeostaticCollapse*Thesis.md.